In a world driven by technology and innovation, the rise of Generative AI promises to revolutionize industries across the board.
Read More
Airo empowers Pharma and life sciences companies to utilize AI technologies to give their stakeholders the tools to improve efficiencies, discover new business opportunities, and more importantly, build stronger relationships with patients.
Read More
The pharmaceutical industry is constantly evolving and facing new challenges, from managing complex supply chains to navigating regulatory requirements. One area that has gained increasing importance in recent years is the use of call center solutions to manage customer and patient interactions.
Read More
We design, create and deploy bots adapted to your specific business needs thanks to our extensive experience in automation, enabling you to cut costs while boosting operational effectiveness.
Read More
In this article, we examine various use cases of robotic process automation in life sciences industry to demonstrate how RPA may assist executives in automating tedious and error-prone operations, producing better analysis, and increasing worker and scientist productivity.
Read More
Consider the benefits of having a bot that can be up and operating in only weeks, is inexpensive to use, is available 24/7, and has a low error rate. Those are Robotic Process Automation (RPA) systems, and they’ve taken the commercial world by storm.
Read More
Traditionally, healthcare, pharma, biotech were lagging digitally. They have never been the leaders because of the regulatory environment they work in.
Read More
2021 has turned out much better than its predecessor, there’s light at the end of this long tunnel and the Covid-19 vaccines are here.
Read More
The healthcare in response to the challenges of the medical pandemic, economic recession, regulatory change, and social dissatisfaction? Scrupulous COVID discussions with a diverse group of industry leaders have helped us define three key themes that can mitigate the lasting impact on the healthcare industry caused by COVID-19.
Read More
As generative AI continues to reshape various industries, its impact on Research and Development (R&D) and Intellectual Property (IP) management has become a focal point of discussion among leaders in Fortune 1000 companies.
Read More